… bench to the patient’s bedside, working on two types of drugs: antagomiRs and miRNA mimics.
The list of miRNA-based drugs in … processes in amyotrophic lateral sclerosis (ALS). In the …

… suffering from the inherited form of amyotrophic lateral sclerosis (ALS) and frontal temporal
… The drug prediction databases DGIdb was used to predict drugs that interact with the TDP-…

… Amyotrophic lateral sclerosis (ALS) is characterized by the selective death of motor … therapy
is considered to be an alternative treatment for ALS, as well as for cell-replacement therapy …

Background: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disorder which affects
the motor neurons. Growing evidence suggests that ALS may impact the metabolic system, …

… In order to progress therapies from the bench to the bedside, biomarkers of disease that …
Encouragingly, ASO treatment of mouse models has been shown to lead to durable, decreased …

… Our findings can possibly support new bedside assessments of the functional status of ALS’
brain … patterns of the disease and lead to more efficient diagnostic and treatment methods. …

… drug AmX0035 has beneficial effects on survival and function in people with amyotrophic
lateral sclerosis (… The two drugs individually exhibit neuroprotective properties in experimental …

… new therapeutic targets and updating clinical treatment strategies for … ), amyotrophic lateral
sclerosis (ALS), Parkinson’s disease (PD), Huntington’s disease (HD), and multiple sclerosis (…

… motor neurons in amyotrophic lateral sclerosis (ALS) [191], in … Identifying novel drugs or
repurposing old drugs depends on our … to be brought from bench to bedside, when purinergic …

… the pathogenesis of sporadic Amyotrophic Lateral Sclerosis (sALS) is … Amyotrophic Lateral
Sclerosis (ALS) is a progressive … primary therapy for ALS with a very limited number of drugs …